Erudio Healtherudio.com
Sponsor
BioNTech trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by BioNTech: ROSETTA Lung-02 and ROSETTA Lung-107. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 7 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (BioNTech SE; BioNTech Cell & Gene Therapies GmbH). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| ROSETTA Lung-02 NCT06712316 · BioNTech SE | first-line non-small cell lung cancer | Phase 2/Phase 3 | 146 | 31 | Focused | Nov 2, 2026 | Preview |
| ROSETTA Lung-107 NCT06841055 · BioNTech SE | first- or second-line non-small cell lung cancer | Phase 2 | 13 | 4 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| BNT324-01 NCT06892548 · BioNTech SE StandardView → | advanced lung cancer | Phase 1/Phase 2 | Standard | View | |||
| BNT324-03 NCT07365995 · BioNTech SE StandardView → | metastatic castration-resistant prostate cancer | Phase 3 | Standard | View | |||
| BNT211-01 NCT04503278 · BioNTech Cell & Gene Therapies GmbH FocusedView → | CLDN6-positive relapsed or refractory advanced solid tumors | Phase 1 | Focused | View | |||
| AHEAD-MERIT NCT04534205 · BioNTech SE FocusedView → | first-line HPV16-positive PD-L1-expressing unresectable recurrent or metastatic HNSCC | Phase 2/Phase 3 | Focused | View | |||
| LuCa-MERIT-1 NCT05142189 · BioNTech SE FocusedView → | advanced non-small cell lung cancer | Phase 1 | Focused | View | |||
| TNBC-MERIT NCT02316457 · BioNTech SE FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT04526899 NCT04526899 · BioNTech SE FocusedView → | anti-PD-1-refractory/relapsed unresectable stage III or IV melanoma | Phase 2 | Focused | View | |||